ANAPTYSBIO, INC
ANABNasdaq
$58.00
↑ +7.1%Jul 17 close · end-of-day
Price
1Y↑ +210.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.4B
P/E
—
P/S
7.2
P/B
130.5
EV/EBITDA
33.3
PEG
—
FCF Yield
0.3%
Dividend Yield
—
Revenue (TTM)
$232.4M
Net Income (TTM)
-$26.8M
Free Cash Flow (TTM)
$4.4M
Gross Margin
—
Operating Margin
17.6%
Net Margin
-11.5%
ROE
-210.1%
ROIC
—
Debt / Equity
—
Net Cash
$286.5M
Return 1Y
+212.3%
Company profile
AnaptysBio, Inc. engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
- CEO
- Daniel R. Faga
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- California
- Website
- anaptysbio.com
Management & directors
- Faga DanielPresident, CEO
- Loumeau Eric JCHIEF LEGAL OFFICER
- Lizzul Paul F.Chief Medical Officer
- Mulroy DennisCHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
ANAB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$25.6M↓ -8.0%
Diluted EPS-$1.84↑ +43.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$23.9M | -$56.8M | -$115.2M | -$164.4M | -$114.9M | $47.9M |
| Net income | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
| Diluted EPS | -$0.73 | -$2.11 | -$4.57 | -$6.08 | -$5.12 | -$0.46 |
| Operating cash flow | -$14.2M | -$45.9M | -$73.6M | -$120.8M | -$135.3M | $19.7M |
| Free cash flow | -$14.7M | -$47.3M | -$74.0M | -$121.6M | -$135.7M | $19.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -31.8% | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Net margin | -26.6% | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.0M | $30.0M | $43.1M | $27.8M | $22.3M | $76.3M | $108.2M | $25.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$40.3M | -$22.8M | -$9.7M | -$27.5M | -$26.2M | $34.7M | $66.9M | -$34.6M |
| Net income | -$46.7M | -$32.9M | -$21.8M | -$39.3M | -$38.6M | $15.1M | $49.6M | -$52.9M |
| Diluted EPS | -$1.71 | -$1.14 | -$0.63 | -$1.28 | -$1.34 | $0.52 | $1.64 | -$1.84 |
| Operating cash flow | -$21.3M | -$10.1M | -$66.7M | -$10.7M | -$40.2M | -$27.4M | $98.0M | -$25.9M |
| Free cash flow | -$21.4M | -$10.1M | -$66.9M | -$10.7M | -$40.3M | -$27.4M | $98.0M | -$25.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -367.5% | -75.8% | -22.4% | -99.2% | -117.5% | 45.5% | 61.8% | -135.5% |
| Net margin | -425.3% | -109.4% | -50.5% | -141.6% | -173.5% | 19.8% | 45.8% | -206.9% |
Company news
May 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Schmid John P. | Option exercise | 6,030 | $0.00 | $0.00 | filing |
| 2026-06-15 | RENTON HOLLINGS | Option exercise | 6,030 | $0.00 | $0.00 | filing |
| 2026-06-15 | Orwin John A | Option exercise | 6,030 | $0.00 | $0.00 | filing |
| 2026-04-20 | ANAPTYSBIO, INC | J | 100 | — | — | filing |
| 2026-03-30 | Schmid John P. | Sale | 12,596 | $55.71 | $701,706.79 | filing |
| 2026-03-30 | Schmid John P. | Sale | 7,527 | $56.70 | $426,782.41 | filing |
| 2026-03-30 | Schmid John P. | Sale | 522 | $57.40 | $29,962.23 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 3,662 | $58.62 | $214,651.06 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 3,155 | $64.19 | $202,522.29 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 3,038 | $65.20 | $198,072.13 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 2,592 | $63.35 | $164,203.98 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 2,570 | $57.91 | $148,819.19 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 1,012 | $62.15 | $62,898.33 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 550 | $60.63 | $33,344.52 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 490 | $59.62 | $29,215.61 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 510 | $56.61 | $28,872.63 | filing |
| 2026-03-27 | Faga Daniel· President, CEO | Sale | 100 | $65.99 | $6,599.00 | filing |
| 2026-03-25 | Faga Daniel· President, CEO | Award | 34,300 | — | — | filing |
| 2026-02-11 | LOUMEAU ERIC J· CHIEF LEGAL OFFICER | Sale | 10,000 | $54.00 | $540,000.00 | filing |
| 2026-02-11 | LOUMEAU ERIC J· CHIEF LEGAL OFFICER | Option exercise | 10,000 | $29.70 | $297,000.00 | filing |
| 2026-01-15 | Marquet Magda | Sale | 9,290 | $48.12 | $446,999.50 | filing |
| 2026-01-15 | Marquet Magda | Option exercise | 11,000 | $26.11 | $287,210.00 | filing |
| 2026-01-15 | Marquet Magda | Sale | 1,710 | $48.85 | $83,531.79 | filing |
| 2026-01-08 | Faga Daniel· President, CEO | Sale | 14,281 | $44.71 | $638,503.51 | filing |
| 2026-01-08 | Lizzul Paul F.· Chief Medical Officer | Sale | 3,650 | $44.71 | $163,191.50 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.